For instance, patients with HER2-positive breast cancer are managed differently as compared to women with triple-negative disease [2, 3]; patients with MYH-associated polyposis require thorough medical scrutiny due to an almost 100% risk of developing colorectal cancer before reaching the age of 65 [4, 5]; patients with Alpha-1 Antitrypsin Deficiency who developed chronic obstructive pulmonary disease (AATD-associated COPD) may need augmentation therapy, not indicated for COPD patients with normal serum levels of Alpha-1 Antitrypsin protein (AAT) [6–14]. The gene discussed is SERPINA1; the disease is chronic obstructive pulmonary disease.